Tonix Pharmaceuticals Enters into Exclusive Worldwide Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for the Treatment of COVID-19 - GlobeNewswire

Tonix Pharmaceuticals Enters into Exclusive Worldwide Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for the Treatment of COVID-19  GlobeNewswire

Comments

Popular posts from this blog

22 Essential Oils for Skin Conditions and Types, and How to Use ...

Syphilis: Symptoms, Diagnosis, Treatment, and Prevention